Abstract: One or more complex lipids including gangliosides to achieve particular health benefits including maintaining or increasing cognitive development or maintaining or increasing growth in a foetal, infant or child subject.

Abstract: One or more complex lipids including gangliosides can be used to achieve particular health benefits including maintaining or increasing cognitive development or maintaining or increasing growth in a foetal, infant or child subject.

Abstract: One or more complex lipids including gangliosides to achieve particular health benefits including maintaining or increasing cognitive development or maintaining or increasing growth in a foetal, infant or child subject.

Abstract: Detection of epigenetic alteration, especially methylation, of a gene or a combination of genes, preferably in a perinatal tissue sample such as umbilical cord, for predicting diverse phenotypic characteristics such as propensity for obesity, altered body composition, impaired cognition, low bone mineral content, neuro-behavioural problems and altered cardiovascular structure and function occurring in an individual.

Abstract: A method of delaying or preventing the onset of hypertension in mammals, including predisposed mammals, is disclosed. The method includes the administering of an effective amount of or increasing the effective concentration of growth hormone, an analog thereof or a functionally equivalent ligand.

Abstract: Embodiments of this invention include methods for alleviating hypertension associated with fetal malnutrition in utero, resulting in a post-natal condition known as fetal programming. Factors that lead to fetal programming can be used to predict development of conditions associated with fetal programming. Fetal programming is associated with numerous metabolic consequences, and is also associated with postnatal hypertension. Insulin-like growth factor-1 (IGF-1), analogs of IGF-1 or a compound that can increase the effective concentration of IGF-1 can decrease expression of antiotensin II type 1 receptors in the kidney, and can result in decreased hypertension associated with fetal programming. Use of IGF-1 as either a primary or an adjunct therapy can therefore be used to decrease adverse consequences of hypertension in animals subject to fetal programming.

Abstract: A method of ameliorating or preventing the consequences of fetal programming in an otherwise normal mammal, including the administration to the mammal of an effective amount of insulin-like growth factor (IGF-I), an analogue thereof, or a functionally equivalent ligand.